IngredientsSoy isoflavones are derived from Glycine max (Leguminosae), commonly known as the soybean or soya bean. The soybean is the primary dietary source of isoflavones for human consumption within the family Fabaceae, yielding the compounds daidzein, genistein, and glycitein. Isoflavones are a unique class of plant flavonoids that have a limited distribution in the plant kingdom and may be physically described as colorless, crystalline ketones.
Flavonoids are a subgroup of the larger class of plant polyphenols; flavonoids are further differentiated into isoflavonoids, of which isoflavones are a subcategory. Isoflavones, the most abundant phytoestrogens in soybeans, are structurally similar to 17β-estradiol. The three principal isoflavone aglycones found in soy are:
Genistein, daidzein, and glycitein (and their different chemical forms) comprise approximately 50%, 40%, and 10%, respectively, of total isoflavone content, although there is considerable variation in this ratio among soybean varieties and foods produced from soybeans.
The three isoflavones in soybeans are the β-glucosides genistin, daidzin, and glycitin, and their respective aglycones, genistein, daidzein, and glycitein. The most common and important dietary sources of these isoflavones are soybeans, which contain the following twelve isoflavone isomers: genistein, genistin, 6″-O-malonylgenistin, 6″-O-acetylgenistin; daidzein, daidzin, 6″-O-malonyldaidzin, 6″-O-acetyldaidzin; glycitein, glycitin, 6″-O-malonylglycitin, and 6″-O-acetylglycitin. Ninety-seven to ninety-eight percent of the soybean isoflavones are in the glycosylated form.
In the soybean before processing, the glucosylated isoflavones are esterified with malonic acid at the 6-hydroxyl position of the glucose moiety. This is important because processing to make soy foods may or may not retain the ester group. For instance, for soy foods made from defatted soy flour and then toasted, the malonyl group is decarboxylated to an acetyl group. In fermented soy foods, the glucosyl groups are removed and modification of the isoflavone may have occurred.
The chemical composition, including the isoflavone content, of different soy-food preparations is variable and dependent on soybean strain, growing conditions, harvest time, and processing method. Commonly consumed soy foods that deliver isoflavones include tofu, tempeh, miso, soy milk, and edamame. As dietary supplements, soy products may contain soy protein, isoflavones, or other components. The intake of isoflavones in Asia (China: 6.2–75.7 mg/day; Japan: 22.6–54.3 mg/day) is much higher than in Europe (0.37–4.5 mg/day) and in the USA (0.73–3.3 mg/day), despite considerable variation between individual studies.
For centuries, soybeans and soy protein have been consumed as a staple food and are an important source of high-quality proteins. The rich history of soy began approximately 5,000 years ago on the plains of Eastern Asia. According to Chinese tradition, the soybean was one of the five sacred crops named by the Chinese emperor Sheng-Nung, who reigned 5,000 years ago; historians maintain that Sheng-Nung mentioned the soybean in his "Ben Tsao Gang Mu," written in the year 2838 B.C.
A close examination of soy's history in China reveals that written testimonies were frequently lost and reconstructed over the centuries, making it challenging to trace. The first reliable reports date from the Han dynasty (206 BCE to 220 CE), and they described agricultural practices that could be dated back 2,000 years before reporting, making it difficult to distinguish factual information from myths. Although soy has been cultivated for ages, the destruction of written sources prevents the confirmation of a precise time period for soybean's use as a foodstuff. In fact, it was primarily used as a green manure before the Han dynasty, when the major crops cultivated were millet, wheat, rice, hemp, mung beans, and sesame.
Asian populations have consumed foods made from soybeans for centuries, whereas in the West, certain subpopulations, specifically Seventh-day Adventists and vegetarians, have used soy foods for approximately 100 years, although the quintessential soy food tofu was first introduced on a large scale to the general US population in the early 1970s.
A critical point of historical nuance concerns isoflavone exposure in traditional preparations. By implementing traditional recipes of tempeh and miso, it was possible to obtain foodstuffs containing almost 5 to 10 times less isoflavones than commercial equivalent products. This suggests that the ancient soy consumption, traditionally in Asia, only provided small amounts of estrogenic isoflavones. When compared to commercial foods, the isoflavone content was found to be 20, 2.6, 4.5, and 9.8 times lower in "homemade" soy juice, tofu, tempeh, and miso, respectively.
Isoflavones first came to the attention of the scientific community in the 1940s, as a result of fertility problems observed in sheep grazing on a type of isoflavone-rich clover. In the 1950s, due to their estrogenic effects in rodents, isoflavones were investigated for use as possible growth promoters by the animal feed industry, although shortly thereafter it was demonstrated that isoflavones may also act as antiestrogens.
Phytoestrogens are naturally occurring nonsteroidal phenolic plant compounds that, due to their molecular structure and size, resemble vertebrate steroidal estrogens. The main dietary sources of isoflavones for humans are soybean and soybean products, which contain mainly daidzein and genistein. When they are consumed, they exert estrogenic and/or antiestrogenic effects.
Genistein exhibits greater than 20-fold higher affinity for ERβ than ERα. Binding of isoflavones to estrogen receptors leads to shuttling of the ligand–ER complex to the nucleus and induces the transcription of target genes via the classical genomic pathway. These findings suggest that ERα is critical for mediating the growth-promoting actions of these isoflavones, whereas ERβ may antagonize ERα-mediated proliferation and contribute to tumor suppression.
In addition to binding to nuclear estrogen receptors, 17β-estradiol also binds to the G-protein-coupled estrogen receptor (GPER) and activates the nongenomic estrogen signaling pathway, and isoflavones have been shown to interact with this pathway as well.
Unlike artificial endocrine-disrupting compounds such as pesticides and plasticizers, phytoestrogens are generally viewed as natural compounds that exert health benefits. Soy isoflavones have been proposed as natural selective estrogen receptor modulators (SERMs), which may be useful in the treatment or prevention of cardiometabolic diseases and estrogen-sensitive cancers.
Isoflavones also inhibit the activity of key enzymes that convert androgens to estrogens. In addition, isoflavones have been shown to be anti-proliferative, pro-apoptotic, anti-angiogenic, anti-oxidative, and anti-inflammatory. Soy isoflavones have also been shown to reduce cancer cell growth through estrogen receptor-independent inhibition of DNA topoisomerases and tyrosine kinases.
The two common categories of antidiabetic drugs acting on nuclear receptors known as peroxisome proliferator-activated receptors (PPARs) are the fibrates and glitazones. Researchers have asked whether the soy isoflavones have activities as either "phytofibrates" or "phytoglitazones." Such activity has been confirmed in both in vivo and in vitro studies.
The antioxidant property of the soy isoflavones, namely genistein and daidzein, is well established in different experimental models and also in clinical studies. Genistein, a phytoestrogen capable of crossing the blood-brain barrier, has been reported to exert an antioxidant effect against the insults of ultraviolet (UV) radiation and chemicals.
In nature, isoflavones mostly appear conjugated with sugars as isoflavone-glycosides, the bioavailability and bioactivity of which are low. For their full activity to be realized, aglycones need to be released from these isoflavone-glycosides and, occasionally, metabolized. The transformations necessary are mostly performed by the enzymes of the gut microbiota.
The clinical effectiveness of soy isoflavones may be a function of the ability to biotransform daidzein to the more potent estrogenic metabolite equol, which may enhance the actions of soy isoflavones owing to its greater affinity for estrogen receptors, unique antiandrogenic properties, and superior antioxidant activity. However, not all individuals consuming daidzein produce equol. Only approximately one-third to one-half of the population is able to metabolize daidzein to equol. This high variability in equol production is presumably attributable to interindividual differences in the composition of the intestinal microflora.
The individuals who produce equol comprise approximately 30% of populations consuming Western diets and approximately 60% of populations consuming soy-rich Asian diets. This differential capacity to produce equol is an important potential explanation for the variability in clinical trial results across populations.
The different chemical forms of soy isoflavones determine whether they undergo digestion by intestinal β-glucosidases and hence their uptake from the small intestine, as well as first-pass metabolism by bacterial β-glucosidases and other microflora in the large intestine. Consumption of a soy protein isolate rich in acetylated isoflavone glucosides is associated with a greater than 6-hour delay in the appearance of glucuronidated isoflavones in blood, suggesting that absorption did not occur in the small intestine and was dependent on bacterially induced hydrolysis in the colon.
Menopausal hot flashes (vasomotor symptoms) represent the most extensively studied area of soy isoflavone application. Because up to 80% of menopausal women experience moderate-to-severe vasomotor symptoms and there are some cancer-related concerns with the use of hormone replacement therapy (HRT), soy isoflavones are an alternative of interest, as indicated by the 2023 position statement of The North American Menopause Society (NAMS).
Meta-analytic evidence: A systematic review and meta-analysis was conducted to determine the efficacy of extracted or synthesized soybean isoflavones in the alleviation of hot flashes in perimenopausal and postmenopausal women, conducted according to Cochrane Handbook guidelines. From 277 potentially relevant publications, 19 trials were included. The conclusion was that soy isoflavone supplements, derived by extraction or chemical synthesis, are significantly more effective than placebo in reducing the frequency and severity of hot flashes. Additional studies are needed to further address the complex array of factors that may affect efficacy, such as dose, isoflavone form, baseline hot flash frequency, and treatment duration.
Soy isoflavone supplements or soy protein may help to reduce the frequency and severity of menopausal hot flashes, but the effect may be small, and research results have been mixed. A 2016 systematic review found that soy isoflavones were associated with modest reductions in the frequency of hot flashes and vaginal dryness but no significant reduction in night sweats.
Specific trial data: One randomized clinical trial was performed in 204 patients who complained of hot flashes; the first group received 50 mg isoflavone once daily and the second group received placebo in the same regimen. In another trial, postmenopausal women (n = 84) consumed a vegan diet with soybeans or their usual diet for 12 weeks. Isoflavone intake increased and body weight decreased by 3.6 kg in the vegan group. Severe hot flashes were reduced by 92% in the vegan group (p < 0.001). The main independent predictor of a reduction in severe hot flashes was daidzein. However, this trial involved a mixed dietary intervention, not isolated isoflavones.
Evidence strength: In terms of safety, no long-term human studies are available, and short-term evidence indicates isoflavones have an acceptable safety profile similar to that of a placebo. Though some evidence indicates soy isoflavones are as effective as hormone replacement therapy, they may not be considered an alternative. Results across trials are inconsistent, and the overall effect size is modest, depending substantially on dose, isoflavone form, and the individual's equol-producer status.
Menopausal estrogen loss leads to increased bone loss. Soy isoflavones can act as selective estrogen receptor modulators; their role in bone turnover has been a subject of investigation.
Meta-analytic evidence: PubMed, Scopus, and Embase were searched to find published trials on the effect of soy isoflavones on bone mineral density (BMD) and bone turnover markers. A random-effects inverse-variance model was used to calculate the pooled effects. A total of 5,313 articles were found, screened, and assessed for eligibility, and finally 52 trials were included in the meta-analysis. Consumption of soy isoflavones caused significant improvement in BMD of lumbar spine (mean difference = 0.76%; 95% CI: 0.09–1.42%; p = 0.03), hip (MD = 0.22%; 95% CI: 0.02–0.42%; p = 0.04), and femoral neck (MD = 2.27%; 95% CI: 1.22–3.31%; p < 0.001).
The conclusion of this meta-analysis was that soy isoflavones prevent osteoporosis-related bone loss in any weight status or treatment duration, and they increase BMD in normal-weight subjects while diminishing bone resorption in overweight/obese individuals.
A separate meta-analysis selected 18 randomized controlled trials. Different types of soy phytoestrogens, including genistein extracts, soy isoflavone extracts, soy protein isolate, and foods containing diverse amounts of isoflavones, were examined.
Bone turnover markers: A meta-analysis of included studies revealed some statistically insignificant observations that soy isoflavone intake is associated with a trend toward increased levels of osteocalcin (OC) and bone alkaline phosphatase (BAP), as well as a trend toward reduced levels of pyridinoline (PYD) and deoxypyridinoline (DPD).
Evidence strength: The evidence from multiple meta-analyses of RCTs is moderately strong for BMD improvement, particularly at the lumbar spine and femoral neck in postmenopausal women. However, improvements in bone turnover marker data remain borderline and inconsistent.
Animal and human studies have shown that consumption of soy protein or associated isoflavones has beneficial impacts on risk factors for cardiovascular disease, including lowering liver or blood triglyceride, total and LDL cholesterol levels, increasing HDL cholesterol and the ratio of HDL/LDL cholesterol.
Observational evidence: Soy/soy products consumption was inversely associated with cardiovascular disease (CVD). Participants in the highest category of dietary soy isoflavone intake had a 10% lower risk of all-cause mortality compared with those in the lowest category. A systematic review and dose-response meta-analysis of prospective studies included a total of 23 prospective studies with an overall sample size of 330,826 participants.
RCT evidence and limitations: However, separating the effects of isoflavones from soy protein is difficult. Among 19 studies of soy isoflavones specifically, the average effect on LDL cholesterol and other lipid risk factors was nil. A significant negative association was shown between soy intake and risk of CVD, stroke, and coronary heart disease. However, no associations between soy isoflavones consumption specifically and risk of CVD, stroke, and coronary heart disease were found in the same analysis. Recent evidence suggests an inverse association between soy and endpoints of CVD; however, most of the studies are of prospective observational design, and RCTs are necessary to confirm this association.
Evidence strength: Observational data linking whole soy foods to cardiovascular benefit are reasonably consistent across large cohorts, but isolating the specific contribution of isoflavones in controlled trials remains difficult, and evidence from RCTs using isoflavone extracts alone on lipid endpoints has produced null or inconsistent results.
The relationship between soy isoflavones and breast cancer risk is one of the most investigated and debated areas. Soy and red clover isoflavones are controversial due to purported estrogenic activity and possible effects on breast cancer.
Epidemiological evidence: A meta-analysis mainly derived from case-control studies showed that a high (≥20 mg/day) and moderate (~10 mg/day) isoflavone intake by consumption of soy food reduces the risk of breast cancer in Asian and Asian-American populations by 29% and 12%, respectively, compared to a low isoflavone intake (≤5 mg/day). This effect was dose-dependent (risk reduction about 16% per 10 mg of isoflavones intake per day) and could be observed in both pre- and postmenopausal women. A meta-analysis showed that soy intake was inversely associated with breast cancer risk in Asian but not Western populations, which indicates that protection against breast cancer may require that women consume levels of soy typical in Asian diets.
RCT and mechanistic evidence: Currently there is little evidence to suggest that any potential weak estrogenic effects of dietary isoflavones have a clinically relevant impact on breast tissue in healthy women. Limited data suggest this is also the case for breast cancer survivors. This evidence includes multiple trials showing no effects on breast proliferation or mammographic density and considerable epidemiologic data showing either no effect or a modest protective role of soy/isoflavone intake on breast cancer risk.
In studies of isoflavone RCTs reviewed, isoflavones were provided by soy food or supplements in amounts between 36.5–235 mg/day for a period of 1–36 months. However, in most studies, differences were not detectable between isoflavone and control/placebo treatment despite good adherence to isoflavone treatment, irrespective of the kind of intervention, dose, or duration.
There is a lack of evidence showing harm from use of soy with respect to risk of breast cancer or recurrence, based on long-term observational data. Soy intake consistent with that of a traditional Japanese diet (2–3 servings daily, containing 25–50 mg isoflavones) may be protective against breast cancer and recurrence. Human trials show that soy does not increase circulating estradiol or affect estrogen-responsive target tissues. Prospective data of soy use in women taking tamoxifen does not indicate increased risk of recurrence.
Five RCTs reported on the efficacy of soy for hot flashes in breast cancer patients, showing no significant reductions in hot flashes compared to placebo.
Evidence strength: Observational evidence from Asian populations suggests a modest dose-dependent protective association; this association is not replicated in Western populations consuming lower amounts. Preclinical data indicate complex, concentration- and receptor-dependent effects. Clinical RCT data do not demonstrate harm at dietary or supplemental dose levels studied.
Soy isoflavones are dietary components for which an association has been demonstrated with reduced risk of prostate cancer in Asian populations. However, the exact mechanism by which these isoflavones may prevent the development or progression of prostate cancer is not completely understood. There are a growing number of animal and in vitro studies that have attempted to elucidate these mechanisms. The predominant and most biologically active isoflavones in soy products — genistein, daidzein, equol, and glycitein — inhibit prostate carcinogenesis in some animal models. Cell-based studies show that soy isoflavones regulate genes that control cell cycle and apoptosis.
Epidemiological studies have shown that isoflavones and soy do not increase the risk of prostate cancer. Instead, in the prostate, isoflavones exhibit an anticarcinogenic effect through their antiproliferative, anti-invasive, and pro-apoptotic activities.
Evidence strength: Evidence is largely observational (population studies) and pre-clinical (cell culture and animal models). Dedicated, large-scale RCTs in humans on hard prostate cancer endpoints remain limited. The efficacy and safety of soy isoflavones for preventing or treating cancer of the breast, endometrium, and prostate are not established; evidence from clinical trials is meager and cautionary with regard to a possible adverse effect.
Soy isoflavones were shown to improve learning and memory function in menopausal women. Furthermore, phytoestrogens significantly affect the brain calcium-binding protein calbindin, which acts as a buffer by binding intracellular calcium and plays an important role in mediating cell proliferation, programmed cell death, and neurotoxicity.
Meta-analytic evidence: In a meta-analysis of 16 RCTs (1,386 participants, mean age = 60 years), soy isoflavones were found to improve overall cognitive function (standardized mean difference [SMD] = 0.19; 95% CI: 0.07–0.31).
Evidence strength: Evidence is preliminary. The effect size is small. Most studies are conducted in postmenopausal women, and the cognitive domains most responsive to isoflavone treatment, as well as the optimal dose and duration, remain to be established in larger, longer-duration trials.
The compounds have been found effective in the management of diabetes by acting on peroxisome proliferator-activated receptors. Current meta-analytic evidence indicates that soy isoflavones improve oxidative stress, glycemia, and lipid abnormalities in postmenopausal women. The NCCIH lists systematic reviews and meta-analyses of clinical trials examining the effects of soy products on cardiovascular risk factors in patients with type 2 diabetes and on glycemic control and lipid profiles.
Evidence strength: Evidence is based predominantly on short-term RCTs and meta-analyses thereof. Results are generally favorable for glycemic markers, but heterogeneity across trials (in terms of dose, soy form, and population) limits firm conclusions. Larger, longer-duration trials are needed.
Soy isoflavones are available both as components of whole soy foods and as isolated dietary supplements. Supplement products may contain soy protein, isoflavones, or other soy components.
The 2023 position statement of The North American Menopause Society (NAMS) acknowledged soy isoflavones as an alternative of interest for vasomotor symptom management. No universally agreed-upon standardized dose has been established by regulatory or pharmacopoeial bodies.
In terms of safety, no long-term human studies are available, and short-term evidence indicates that soy isoflavones have an acceptable safety profile similar to that of a placebo. Organizations such as the European Food Safety Authority (EFSA) have evaluated the safety of isoflavones, particularly as food supplements for postmenopausal women, and found no evidence of harm to the mammary glands, uterus, or thyroid function at typical supplementation levels.
Concern about a possible interplay between soy diet and the thyroid has a long history. In the 1930s, McCarrison described the goitrogenic effect of soybeans in rats, and subsequent animal studies suggested this was due to inhibition of thyroid peroxidase by isoflavones, which may reduce triiodothyronine and thyroxine synthesis. In one study, thyroid-stimulating hormone (TSH) serum concentrations increased while free thyroxine (fT4) concentrations decreased with 3 months of soy protein with isoflavones compared to soy protein alone in both men and women.
The clinical significance in healthy adults at typical doses is less clear. The EFSA found no evidence of harm to thyroid function at typical supplementation levels.
The amount of levothyroxine required for adequate thyroid hormone replacement has been found to increase in infants with congenital hypothyroidism fed soy formula. Taking levothyroxine at the same time as a soy protein supplement also increased the levothyroxine dose required for adequate thyroid hormone replacement in an adult with hypothyroidism. However, few data, mainly case reports, seemed to suggest a possible interference of soy products on levothyroxine (L-T4) tablet absorption. The only prospective randomized cross-over study showed no differences in L-T4 absorption when L-T4 and soy isoflavones were consumed concomitantly. The interference of soy products on L-T4 absorption, if present, seems to have little clinical impact.
High intakes of soy protein may interfere with the efficacy of the anticoagulant medication warfarin. There is one case report of an individual on warfarin who developed subtherapeutic international normalized ratio (INR) values upon consuming approximately 16 ounces of soy milk daily for four weeks. INR values returned to therapeutic levels two weeks after discontinuing soy milk.
Until more is known about potential interactions in humans, those taking tamoxifen or other selective estrogen receptor modulators (SERMs) to treat or prevent breast cancer should be cautious and seek medical advice regarding the use of soy protein supplements or isoflavone extracts. Prospective data of soy use in women taking tamoxifen does not indicate increased risk of recurrence, though caution in this population is widely recommended pending further data.
It is uncertain whether soy isoflavone supplements are safe for women at high risk of breast cancer or with a history of breast cancer. In cell cultures or in animal models, the estrogenicity and biological effects of soy isoflavones are often concentration- or dose-dependent, much like estrogens, and are cell-type specific as well as species-dependent. Under low estrogen conditions, low doses of isoflavones stimulate the growth of hormone-dependent breast cancer cells in cultures, but high doses of isoflavones inhibit breast cancer cell proliferation. Human epidemiological and clinical data, however, have not demonstrated adverse effects at dietary or commonly supplemented levels.
Anti-fertility effects have been observed in sheep but not in other species. The differential ability to produce equol — the active metabolite of daidzein — significantly affects individual response and complicates extrapolation between studies and populations. The interpersonal variations in the gut microbiome complicate the interpretation of data collected from humans. Furthermore, because rodents are efficient equol-producers, translatability between rodent models and humans is challenging.
Preliminary clinical research and a case report suggest that soy-based formulas inhibit the absorption of levothyroxine in infants with congenital hypothyroidism. A levothyroxine dosage increase may be needed for infants with congenital hypothyroidism while using soy-based formulas, and the dose may need to be reduced when soy-based formulas are no longer administered.
Health conditions that Soy isoflavones may help support.
Soy isoflavones are established polyphenolic antioxidants that scavenge reactive oxygen species, enhance antioxidant enzyme activity, and reduce lipid peroxidation markers in human clinical studies.
Soy isoflavones (genistein, daidzein) act as phytoestrogens that improve endothelial function via eNOS upregulation, reducing arterial stiffness particularly in postmenopausal women. A 2024 PMC literature review explicitly listed soy isoflavones among nutraceuticals associated with greater endothelial function and decreased arterial stiffness. Meta-analyses of RCTs confirm blood pressure reduction and improved FMD.
A 2024 meta-analysis of 24 RCTs (1,945 participants) found soy isoflavone supplementation significantly reduces both systolic and diastolic blood pressure, with more pronounced effects in metabolic syndrome or prehypertensive individuals and interventions ≥6 months.
Multiple RCTs and meta-analyses indicate soy isoflavones can modestly improve fasting glucose and insulin levels, particularly in individuals with metabolic syndrome or prediabetes. Effects appear strongest with whole soy versus isolated isoflavones. Results across studies are heterogeneous.
Soy isoflavones (principally genistein and daidzein) bind estrogen receptors in bone, stimulating osteoblasts and inhibiting osteoclasts. A systematic review of 18 RCTs in postmenopausal women found significant positive effects on lumbar spine and femoral neck BMD, and they are recognized in osteoporosis literature as botanicals with measurable bone effects at 30–126 mg/day.
Soy isoflavones (genistein, daidzein) modulate lipid metabolism through estrogen receptor pathways and hepatic LDL receptor upregulation. Meta-analyses report modest TC and LDL-C reductions; evidence is more variable than for soy protein as a whole.
Soy isoflavones modulate key inflammatory signaling pathways and have been examined for their effect on C-reactive protein (CRP) in multiple RCTs. Overall evidence shows a non-significant average CRP reduction, though subgroup analyses favor older participants with higher baseline CRP.
Clinical evidence from multiple RCTs and a meta-analysis of 16 trials suggests soy isoflavones can modestly slow or attenuate cognitive decline in older adults, with benefits in memory and overall cognitive function. Evidence is heterogeneous and equol-producer status may be a key moderator.
Soy isoflavones (genistein, daidzein) inhibit tyrosinase and melanin synthesis, and have phytoestrogenic activity that may support skin thickness and collagen content in the periorbital area. They are part of the mechanistic basis for soy's inclusion in authoritative reviews on natural depigmenting agents for hyperpigmentation. Listed among natural agents with clinical evidence in the JCAD systematic review (2018).
There is emerging clinical evidence that soy isoflavones may reduce depressive symptoms, particularly in peri- and postmenopausal women, likely via estrogenic modulation of mood-related pathways. Evidence from clinical trials is mixed but partially supportive.
Soy isoflavones (primarily genistein and daidzein) are well-documented phytoestrogens that bind estrogen receptors with ERβ preference, modestly reducing menopausal hot flash frequency and intensity. Multiple RCTs and systematic reviews support their use at ≥50 mg/day for menopausal vasomotor symptoms and bone density maintenance.
Soy isoflavones (principally genistein and daidzein) inhibit 5-alpha reductase and have anti-androgenic effects relevant to androgenetic alopecia. Daidzein is metabolized by gut bacteria to equol, which specifically binds and sequesters DHT. Soy isoflavone-containing preparations have been studied in hair loss contexts including the capsaicin/isoflavone RCT showing improved hair count.
Soy isoflavones have demonstrated anti-aging effects across multiple biological systems including bone, skin, cardiovascular, and antioxidant defense, supporting their role as broad healthy-aging agents. Evidence comes from numerous RCTs predominantly in postmenopausal women.
Soy isoflavones have been studied extensively for cardiovascular risk reduction. A 2021 meta-analysis in postmenopausal women found modest but significant decreases in total cholesterol and increases in HDL. Observational evidence links higher soy isoflavone intake with reduced CVD risk.
Soy isoflavones (primarily genistein and daidzein) have been studied in numerous RCTs for menopausal hot flashes with mixed but partially positive results. Several systematic reviews support modest efficacy, particularly in equol-producing individuals and those with higher baseline hot flash frequency. Classified as scientifically studied though not universally efficacious.
Soy isoflavones, particularly genistein and daidzein, inhibit melanogenesis and reduce UV-induced pigmentation. Genistein inhibits melanocyte proliferation and melanosome transfer; clinical evidence supports the overall soy category's efficacy for hyperpigmentation treatment.
Soy isoflavones (genistein and daidzein) dose-dependently decrease detrusor contractions via K+(Ca) channel activation. A cross-sectional study in 2,000 elderly Chinese men found higher soy isoflavone intake linked to lower LUTS risk. Animal studies show benefit for detrusor overactivity in estrogen-deficient rats. Clinical RCTs in women using pumpkin/soy germ combinations demonstrate reductions in OAB symptoms and urinary incontinence.
Soy isoflavones activate PPAR receptors and modulate insulin signaling pathways. RCT and meta-analytic evidence suggests modest improvements in HOMA-IR, particularly in women with PCOS or metabolic syndrome.
Soy isoflavones have been clinically studied in women with PCOS—a leading cause of irregular cycles—showing improvements in hormonal balance including reductions in testosterone and LH with increases in estradiol and FSH. Clinical evidence in PCOS is supported by RCTs.
In patients with chronic kidney disease (CKD), soy protein containing isoflavones has been associated with reductions in proteinuria, serum creatinine, and CRP in predialysis populations. A meta-analysis of 12 RCTs supports a nephroprotective signal.
Multiple RCTs and a meta-analysis of 16 trials support a modest beneficial effect of soy isoflavones on memory and overall cognitive function in older adults. Results are mixed across individual studies, with equol-producer status appearing to modulate response.
Soy isoflavones (genistein, daidzein, glycitein) are phytoestrogens shown in multiple RCTs and meta-analyses to modestly reduce hot flash frequency and severity in menopausal women. A 2012 meta-analysis found extracted/synthesized soy isoflavones significantly reduced hot flash frequency. Evidence for bone health is also present, though less conclusive.
Multiple RCTs in patients with metabolic syndrome show that soy isoflavone supplementation reduces triglycerides, LDL cholesterol, total cholesterol, and waist circumference. A dedicated RCT in older women with metabolic syndrome supports these findings.
Soy isoflavones are phytoestrogens with documented bone-protective effects in menopausal women. A meta-analysis showed soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women. The MDPI 2021 meta-analysis of 63 RCTs found beneficial effects on BMD from soy isoflavones, though results are mixed across individual trials.
Soy isoflavones (primarily genistein and daidzein) have been studied for OAB via multiple mechanisms. A 2014 RCT (n=120) of a pumpkin seed + soy germ extract combination significantly reduced urination frequency, urgency, and nocturia versus placebo. A cross-sectional study of 2,000 elderly Chinese men found dietary soy isoflavone intake was linked to a lower risk of lower urinary tract symptoms. In vitro, genistein and daidzein dose-dependently decrease detrusor contractions.
Soy isoflavones (genistein, daidzein) have phytoestrogenic and insulin-sensitizing properties studied in PCOS. Systematic reviews list soy isoflavones among nutritional supplements with evidence in PCOS, showing improvements in androgen levels, SHBG, insulin resistance, and lipid profiles.
Soy isoflavones (genistein, daidzein, glycitein) are phytoestrogens that bind ERβ and exert mild estrogenic effects useful in perimenopause. A 2025 meta-analysis of 12 RCTs (533 participants) found statistically significant benefit for menopausal symptoms (Hedges' g = −0.25). Evidence supports reduction in hot flash frequency and potential bone benefit.
Soy isoflavones are the phytoestrogenic compounds responsible for soy's effects on PMS. Isoflavones genistein and daidzein bind estrogen receptors with SERM-like activity and may modulate the hormonal environment of PMS. RCT evidence is preliminary but present in systematic reviews.
Soy isoflavones (genistein, daidzein, glycitein) have been examined in RCTs for prostate cancer prevention and PSA modulation. Epidemiological data consistently show lower prostate cancer rates in populations with high soy intake. Multiple RCTs have investigated soy isoflavones in men with prostate cancer or elevated risk. A 2020 evidence analysis of RCTs includes soy isoflavones as an examined intervention for PSA modulation.
Several double-blind RCTs demonstrate that oral soy isoflavone supplementation reduces fine wrinkles and improves facial skin texture in middle-aged and postmenopausal women. Effect sizes are modest but statistically significant.
Clinical and in vitro evidence shows soy isoflavones stimulate dermal collagen synthesis, increase epidermal thickness, and improve skin elasticity, particularly in estrogen-deficient postmenopausal women.
Soy isoflavones (genistein, daidzein, equol) have evidence from RCTs and meta-analyses for modest TG reduction, particularly in menopausal women and metabolic syndrome patients. They act via phytoestrogenic and PPAR-alpha/gamma mechanisms to modulate lipid metabolism.
Clinical trials show soy isoflavones modestly improve vaginal dryness symptoms in postmenopausal women via estrogenic effects on vaginal epithelium. A systematic review found a significant reduction in vaginal dryness, though improvements in the vaginal maturation index were statistically non-significant.
Body systems that Soy isoflavones may help support.
Go back